8k addresses the issue with Medmar, which I posted
Post# of 15624
(Total Views: 342)
Posted On: 05/03/2017 6:47:02 AM
8k addresses the issue with Medmar, which I posted previously if anyone noticed that Medmar was removed from the presentation.
And the bigger subject is an update on the multiple myeloma trials and will be completed during Q3 and to peruse FDA orphan designation status.
PR will be released this morning.
http://www.otcmarkets.com/edgar/GetFilingHtml...D=12035254
On April 21, 2017, OWC Pharmaceutical Research Corp.'s wholly-owned Israeli subsidiary, One World Cannabis Ltd (collectively, the "Company" or OWC"
served written notice on Medmar LLC("Medmar" of OWC's determination to prepay the loan by Medmar to OWC in the principal amount of $300,000. Reference is made to the Company's Form 8-K filed with the SEC on September 30, 2016 and to the Loan Agreement between OWC and Medmar, filed as Exhibit 10.9 to the September 30, 2016 Form 8-K. Pursuant to Sections 4 and 5.3 of the Loan Agreement and based upon the full repayment of the non-recourse, non-interest bearing and non-convertible loan, OWC has elected to exercise what it believes is its absolute right to terminate certain distribution rights granted to Medmar under the loan agreement .
Item 8.01. Other Events.
The Company is filing this Current Report on Form 8-K announcing that it is publishing a press release titled "OWC Pharmaceutical Research Announces Update on Multiple Myeloma Study," tomorrow, May 3, 2017. The press release, attached as Exhibit 99.1 hereto, reports OWC's intention to continue its testing and study of its cannabinoid-based therapies on the treatment of multiple myeloma.
The next phase of the study, which is based upon the promising results of OWC's earlier in-vitro studies of its unique formula of cannabinoid-based therapies targeting cells, is to investigate the doses and diverse delivery systems, [e.g. per os/oral vs. per rectum] to best determine the most effective dosages and means of delivery for thefuture planned study on human patients, pending receipt of regulatory approvals. The Company expects that the continued study will be completed during Q3 of this year.
Dr. Yehuda Baruch, the Company's Chief Science Officer and Director of Research and Regulatory Affairs of OWC, stated that this unique study, which we designed to pursue and secure FDA orphan designation status, will hopefully open ways to improve the quality of life of multiple myeloma patients while at the same time potentially enhance response to various multiple myeloma treatment regimes.
Item 9.01 Financial Statements and Exhibits.
(a) The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.
Exhibit No.
Description
99.1 Press Release dated May 3, 2017, filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OWC Pharmaceutical Research Corp.
By: /s/ Mordechai Bignitz
Name: Mordechai Bignitz
Title: Chief Executive Officer
Date: May 2, 2017
OWC Pharmaceutical Research Announces Update on Multiple Myeloma Study
PETACH TIKVA, Israel, May 3, 2017
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company" , an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that the Scientific Advisory Team of its wholly owned Israeli subsidiary, One World Cannabis Ltd. ("OWC" has determined the road map for continuing the Multiple Myeloma study.
The purpose of the next phase of the study, which is based upon the promising results of the Company's earlier in-vitro studies of its unique formula of cannabinoid-based therapies targeting cells, is to investigate the doses and diverse delivery systems, [e.g. per os/oral vs. per rectum] in order to best determine the most effective dosages and means of delivery for a future the planned study on human patients following receipt of regulatory approvals. The Company expects that the continued study will be completed during Q3 of this year.
Dr. Yehuda Baruch, the Company's Chief Science Officer and Director of Research and Regulatory Affairs of OWC stated "after in-depth and extensive review and assessment of the study's results accumulated so far, OWC's research committee determined that the medical and scientific accepted multiple myelomamice model is the best way to progress, compared to other possible known scientific paths. This unique study, which we designed to pursue and secure FDA orphan designation status, will hopefully open ways to improve the quality of life of multiple myeloma patients while at the same time may potentially enhance response to various multiple myeloma treatment regimes.
The initial OWC study was conducted at the Israeli-renowned Academic Medical Center (affiliated with Tel-Aviv University) using three repetitive tests on the effect of OWC's proprietary cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50% concentration). The results from our earlier study demonstrated more than 60% malignant cell death. In view of the basic study results, OWC has begun the development of a unique formulation that includes cannabis extracts for a new delivery system in the form of a cannabis dissoluble tablet to treat multiple myeloma. The cannabis dissoluble tablet will provide physicians with the ability to control and administrate optimal dosage. This can be treated with every multiple myeloma patient and will replace the common usage of smoking medical cannabis today which is not widely accepted by scientists and physicians as smoking, edibles and oil extracts with no meaningful or substantial dosage control.
And the bigger subject is an update on the multiple myeloma trials and will be completed during Q3 and to peruse FDA orphan designation status.
PR will be released this morning.
http://www.otcmarkets.com/edgar/GetFilingHtml...D=12035254
On April 21, 2017, OWC Pharmaceutical Research Corp.'s wholly-owned Israeli subsidiary, One World Cannabis Ltd (collectively, the "Company" or OWC"
served written notice on Medmar LLC("Medmar" of OWC's determination to prepay the loan by Medmar to OWC in the principal amount of $300,000. Reference is made to the Company's Form 8-K filed with the SEC on September 30, 2016 and to the Loan Agreement between OWC and Medmar, filed as Exhibit 10.9 to the September 30, 2016 Form 8-K. Pursuant to Sections 4 and 5.3 of the Loan Agreement and based upon the full repayment of the non-recourse, non-interest bearing and non-convertible loan, OWC has elected to exercise what it believes is its absolute right to terminate certain distribution rights granted to Medmar under the loan agreement . Item 8.01. Other Events.
The Company is filing this Current Report on Form 8-K announcing that it is publishing a press release titled "OWC Pharmaceutical Research Announces Update on Multiple Myeloma Study," tomorrow, May 3, 2017. The press release, attached as Exhibit 99.1 hereto, reports OWC's intention to continue its testing and study of its cannabinoid-based therapies on the treatment of multiple myeloma.
The next phase of the study, which is based upon the promising results of OWC's earlier in-vitro studies of its unique formula of cannabinoid-based therapies targeting cells, is to investigate the doses and diverse delivery systems, [e.g. per os/oral vs. per rectum] to best determine the most effective dosages and means of delivery for thefuture planned study on human patients, pending receipt of regulatory approvals. The Company expects that the continued study will be completed during Q3 of this year.
Dr. Yehuda Baruch, the Company's Chief Science Officer and Director of Research and Regulatory Affairs of OWC, stated that this unique study, which we designed to pursue and secure FDA orphan designation status, will hopefully open ways to improve the quality of life of multiple myeloma patients while at the same time potentially enhance response to various multiple myeloma treatment regimes.
Item 9.01 Financial Statements and Exhibits.
(a) The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.
Exhibit No.
Description
99.1 Press Release dated May 3, 2017, filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OWC Pharmaceutical Research Corp.
By: /s/ Mordechai Bignitz
Name: Mordechai Bignitz
Title: Chief Executive Officer
Date: May 2, 2017
OWC Pharmaceutical Research Announces Update on Multiple Myeloma Study
PETACH TIKVA, Israel, May 3, 2017
OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"
, an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that the Scientific Advisory Team of its wholly owned Israeli subsidiary, One World Cannabis Ltd. ("OWC" has determined the road map for continuing the Multiple Myeloma study. The purpose of the next phase of the study, which is based upon the promising results of the Company's earlier in-vitro studies of its unique formula of cannabinoid-based therapies targeting cells, is to investigate the doses and diverse delivery systems, [e.g. per os/oral vs. per rectum] in order to best determine the most effective dosages and means of delivery for a future the planned study on human patients following receipt of regulatory approvals. The Company expects that the continued study will be completed during Q3 of this year.
Dr. Yehuda Baruch, the Company's Chief Science Officer and Director of Research and Regulatory Affairs of OWC stated "after in-depth and extensive review and assessment of the study's results accumulated so far, OWC's research committee determined that the medical and scientific accepted multiple myelomamice model is the best way to progress, compared to other possible known scientific paths. This unique study, which we designed to pursue and secure FDA orphan designation status, will hopefully open ways to improve the quality of life of multiple myeloma patients while at the same time may potentially enhance response to various multiple myeloma treatment regimes.
The initial OWC study was conducted at the Israeli-renowned Academic Medical Center (affiliated with Tel-Aviv University) using three repetitive tests on the effect of OWC's proprietary cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50% concentration). The results from our earlier study demonstrated more than 60% malignant cell death. In view of the basic study results, OWC has begun the development of a unique formulation that includes cannabis extracts for a new delivery system in the form of a cannabis dissoluble tablet to treat multiple myeloma. The cannabis dissoluble tablet will provide physicians with the ability to control and administrate optimal dosage. This can be treated with every multiple myeloma patient and will replace the common usage of smoking medical cannabis today which is not widely accepted by scientists and physicians as smoking, edibles and oil extracts with no meaningful or substantial dosage control.
(0)
(0)